Chordoma Clinical Trial
Official title:
Immunohistochemical Study of Chordomas to Improve Their Diagnosis and Prognosis Care
Chordomas are very rare malignant tumors, chemo-resistant with high propensity for recurrence. The role of immunotherapy in these patients remains largely unexplored while PD-L1 and CD8 status in the micro-environment of chordomas is basically not known. Similarly, this tumor often poses diagnostic difficulties due to its resemblance with metastasis or chondrosarcoma, thus, it would be useful to know the expression status of factors used during the work-up of metastatic or mesenchymal tumors, like CDX2, INSM1 and FOXA1, which remains unknown for chordomas. Thus, the aim of the study is to explore PD-L1, CD8, CDX2, INSM1 and FOXA1 expression in a series of chordomas and compare it with clinico-pathological and prognostic features.
Retrospective, non-interventional study. A series of chordomas will be analyzed for detailed histologic features and for various immunohistochemical factors and results will be compared with clinical factors, like overall and disease-free survival. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03955042 -
Pemetrexed for the Treatment of Chordoma
|
Phase 1 | |
| Completed |
NCT01347307 -
Stereotactic Body Radiotherapy for Spine Tumors
|
N/A | |
| Active, not recruiting |
NCT00496119 -
Proton Beam Therapy for Chordoma Patients
|
Phase 2 | |
| Recruiting |
NCT06029218 -
Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy
|
N/A | |
| Completed |
NCT03595228 -
BN Brachyury and Radiation in Chordoma
|
Phase 2 | |
| Recruiting |
NCT06140732 -
Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma
|
Phase 2 | |
| Active, not recruiting |
NCT01175109 -
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
|
Phase 1 | |
| Completed |
NCT00150072 -
Efficacy and Safety of Imatinib in Chordoma
|
Phase 2 | |
| Terminated |
NCT00003926 -
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05041127 -
Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma
|
Phase 2 | |
| Recruiting |
NCT05861245 -
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base
|
N/A | |
| Completed |
NCT00464620 -
Trial of Dasatinib in Advanced Sarcomas
|
Phase 2 | |
| Recruiting |
NCT03242382 -
Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.
|
Phase 2 | |
| Completed |
NCT02520128 -
A Study of IMRT in Primary Bone and Soft Tissue Sarcoma
|
N/A | |
| Recruiting |
NCT01567046 -
Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas
|
N/A | |
| Recruiting |
NCT02986516 -
Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease
|
N/A | |
| Completed |
NCT00919269 -
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
|
||
| Active, not recruiting |
NCT02989636 -
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
|
Phase 1 | |
| Active, not recruiting |
NCT03083678 -
Afatinib in Locally Advanced and Metastatic Chordoma
|
Phase 2 | |
| Completed |
NCT00713037 -
Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas
|
N/A |